Document:

Exhibit 4.3

 

Officers’ Certificate
  Pursuant to Sections 201, 301 and 303 of the Indenture

 

 

Dated: June 19, 2019

 

The undersigned, Paul M. Meurer, Executive Vice President, Chief Financial Officer and Treasurer, and Michael R. Pfeiffer, Executive Vice President, Chief Administrative Officer, General Counsel and Secretary, of Realty Income Corporation, a Maryland corporation (the “Company”), hereby certify as follows:

 

The undersigned, having read the appropriate provisions of the Indenture dated as of October 28, 1998 (the “Indenture”) between the Company and The Bank of New York Mellon Trust Company, N.A., as successor trustee (the “Trustee”), including Sections 201, 301 and 303 thereof and the definitions in such Indenture relating thereto, and certain other corporate documents and records, and having made such examination and investigation as, in the opinion of the undersigned, each considers necessary to enable the undersigned to express an informed opinion as to whether or not conditions set forth in the Indenture relating to the establishment of the title and terms of the Company’s 3.250% Notes due 2029 (the “Securities”), which will constitute a new series of the Company’s debt securities under the Indenture, and the form of certificate evidencing the Securities of such series have been complied with, and whether the conditions in the Indenture relating to the authentication and delivery by the Trustee of the Securities of such series have been complied with, certify that (i) the title and terms of the Securities of such series were established by the undersigned pursuant to authority delegated to them by resolutions duly adopted by the Board of Directors of the Company on October 16, 2018 and June 11, 2019 (the “Resolutions”) and such terms are set forth in Annex A hereto, (ii) the form of certificate evidencing the Securities of such series was established by the undersigned pursuant to authority delegated to them by the Resolutions and shall be in substantially the form attached hereto as Annex B (it being understood that, in the event that the Securities of such series are ever issued in definitive certificated form, the legends appearing as the first two paragraphs on the first page of such form of certificate evidencing the Securities of such series may be removed), (iii) a true, complete and correct copy of the Resolutions, which were duly adopted by the Board of Directors of the Company and are in full force and effect in the form adopted on the date hereof, are attached as Annex C hereto and are also attached as an exhibit to the Certificate of the Secretary of the Company of even date herewith, (iv) the form, title and terms of the Securities of such series have been established pursuant to and in accordance with Sections 201 and 301 of the Indenture and comply with the Indenture and, in the opinion of the undersigned, all conditions provided for in the Indenture (including, without limitation, those set forth in Sections 201, 301 and 303 of the Indenture) relating to the establishment of the title and terms of the Securities of such series, the form of certificate evidencing the Securities of such series and the execution, authentication and delivery of the Securities of such series have been complied with and (v) to the best knowledge of the undersigned, no Event of Default (as defined in the Indenture) has occurred and is continuing with respect to the Securities.

 

[SIGNATURE PAGE FOLLOWS]

 

 

IN WITNESS WHEREOF, we have hereunto set our hands as of the date first written above.

 

 

	
 
    	
/s/ Paul M. Meurer
    
	
 
    	
Paul M. Meurer
    
	
 
    	
Executive Vice President, Chief Financial Officer
    
	
 
    	
and Treasurer
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
/s/ Michael R. Pfeiffer
    
	
 
    	
Michael R. Pfeiffer
    
	
 
    	
Executive Vice President, Chief Administrative Officer, General   Counsel and Secretary
    

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Signature Page to Officers’ Certificate 
 Pursuant to Sections 201, 301 and 303 of the Indenture

 

 

ANNEX A

 

 

Terms of the 3.250% Notes due 2029

 

 

FOR PURPOSES OF THIS ANNEX A, THE TERM “SECURITIES” SHALL HAVE THE MEANING SET FORTH IN CLAUSE (1) BELOW.  OTHER CAPITALIZED TERMS USED IN THIS ANNEX A AND NOT OTHERWISE DEFINED HEREIN HAVE THE SAME DEFINITIONS AS IN THE INDENTURE REFERRED TO IN THE OFFICERS’ CERTIFICATE OF WHICH THIS ANNEX A CONSTITUTES A PART.

 

(1)                              A series of debt securities is hereby established under the Indenture, and such series of debt securities shall be known and designated as the “3.250% Notes due 2029” (the “Securities”).

 

(2)                              The aggregate principal amount of the Securities of such series which may be authenticated and delivered under the Indenture is limited to $500,000,000, except for Securities of such series authenticated and delivered upon registration of transfer of, or in exchange for, or in lieu of, other Securities of such series pursuant to Sections 304, 305, 306, 906 or 1107 of the Indenture; provided, however, that such series of Securities may be re-opened by the Company for the issuance of additional Securities of such series, so long as any such additional Securities of such series have the same form and terms (other than, if applicable, the offering price, underwriting or other discounts and commissions, the original date of issuance, the first date on which interest thereon shall be payable and the date from which interest thereon shall begin to accrue), and carry the same right to receive accrued and unpaid interest, as the Securities of such series theretofore issued; provided, however, that, notwithstanding the foregoing, such series of Securities may not be reopened if the Company has effected defeasance or covenant defeasance with respect to the Securities of such series pursuant to Section 1402 and 1403, respectively, of the Indenture or has effected satisfaction and discharge with respect to the Securities of such series pursuant to Section 401 of the Indenture.

 

(3)                              The Securities of such series are issuable only as Registered Securities without coupons and may, but need not, bear a corporate seal.  The Securities of such series shall initially be issued in book-entry form and represented by one or more permanent Global Securities of such series, the initial depositary (the “Depositary”) for the Global Securities of such series shall be The Depository Trust Company and the depositary arrangements shall be those employed by whoever shall be the Depositary with respect to the Global Securities of such series from time to time.  Notwithstanding the foregoing, certificated Securities of such series in definitive form (“Certificated Securities”) may be issued in exchange for Global Securities of such series under the circumstances contemplated by Section 305 of the Indenture.

 

(4)                              The Securities of such series shall be sold by the Company to the several underwriters named in the Purchase Agreement dated June 12, 2019, for whom Citigroup Global Markets Inc., BNY Mellon Capital Markets, LLC, Credit Suisse Securities (USA) LLC, Goldman Sachs & Co. LLC, Mizuho Securities USA LLC and U.S. Bancorp Investments, Inc. are acting as representatives, at a price equal to 98.709% of the principal amount thereof.  The initial price to public of the Securities shall be 99.359% of the principal amount thereof, plus accrued interest from June 19, 2019 if settlement occurs after that date.  Underwriting discounts and commissions shall be 0.650% of the principal amount of the Securities.

 

(5)                              The final maturity date of the Securities on which the principal thereof is due and payable shall be June 15, 2029.

 

 

(6)                              The principal of the Securities of such series shall bear interest at the rate of 3.250% per annum from June, 19 2019 or from the most recent date to which interest has been paid or duly provided for, payable semiannually in arrears on June 15 and December 15  (each, an “Interest Payment Date”) of each year, commencing December 15, 2019, to the Persons in whose names the Securities of such series (or one or more Predecessor Securities of such series) are registered at the close of business on the June 1 and December 1 (each, a “Regular Record Date”), respectively, immediately prior to such Interest Payment Dates, regardless of whether such Regular Record Date is a Business Day.  Interest on the Securities will be computed on the basis of a 360-day year of twelve 30-day months.  If any principal of, or premium, if any, or interest on, any of the Securities of such series is not paid when due, then such overdue principal and, to the extent permitted by law, such overdue premium or interest, as the case may be, shall bear interest until paid or until such payment is duly provided for at the rate of 3.250% per annum.

 

(7)                              Los Angeles, California is hereby designated as a Place of Payment for the Securities of such series.  The place where the principal of and premium, if any, and interest on the Securities of such series shall be payable, where Securities of such series may be surrendered for the registration of transfer or exchange, and where notices or demands to or upon the Company in respect of the Securities of such series and the Indenture may be served shall be the office or agency maintained by the Company for such purpose in Los Angeles, California, which shall initially be an office of the Trustee in Los Angeles, California, which on the date hereof is located at The Bank of New York Mellon Trust Company, N.A., Attention: Corporate Trust Administration, 400 South Hope Street, Suite 500, Los Angeles, CA 90071; provided, that, so long as any Certificated Notes (as defined in the form of Security of such series which appears as Annex B to the Officers’ Certificate of which this Annex A is a part) are outstanding, the Borough of Manhattan, The City of New York shall also be a Place of Payment for the Securities of such series and the Company will maintain an office or agency in the Borough of Manhattan, The City of New York where the principal of and premium, if any, and interest on the Securities of such series shall be payable, where Securities of such series may be surrendered for registration of transfer or exchange, and where notices or demands to or upon the Company in respect of the Securities of such series and the Indenture may be served.

 

(8)                              The Securities of such series are redeemable at any time, as a whole or from time to time in part, at the option of the Company on the terms and subject to the conditions set forth in the Indenture and in the form of Security of such series which appears as Annex B to the Officers’ Certificate of which this Annex A is a part; provided that, if less than all of the Outstanding Securities of such series (including, without limitation, any Outstanding Securities of such series issued upon a re-opening of such series) are to be redeemed, the Securities of such series (or portions thereof) to be redeemed shall be selected, in the case of Securities of such series in book-entry form evidenced by one or more Global Securities, in accordance with the applicable procedures of the Depositary or, in the case of any Certificated Securities of such series, by such method as the Trustee shall deem fair and appropriate, all as further provided in the Indenture, and, for the avoidance of doubt, it is understood and agreed that the foregoing selection of Securities of such series (or portions thereof) for redemption shall be made from among all of the Outstanding Securities of such series (including, without limitation, any Outstanding Securities of such series issued upon a re-opening of such series), treated as a single class.

 

(9)                              The Securities of such series shall not be repayable or redeemable at the option of the Holders prior to the final maturity date of the principal thereof (except as provided in Article Five of the Indenture) and shall not be subject to a sinking fund or analogous provision.

 

(10)                      The Securities of such series shall be issued in minimum denominations of $2,000 and integral multiples of $1,000 in excess thereof.

 

 

(11)                      The Trustee shall be the initial trustee, Security Registrar, transfer agent and Paying Agent for the Securities of such series.

 

(12)                      The entire outstanding principal amount of the Securities of such series shall be payable upon declaration of acceleration of the maturity of the Securities of such series pursuant to Section 502 of the Indenture.

 

(13)                      Payment of the principal of and premium, if any, and interest on the Securities of such series shall be made in Dollars and the Securities of such series shall be denominated in Dollars.

 

(14)                      Other than amounts payable upon redemption of the Securities at the option of the Company prior to March 15, 2029, the amount of payments of principal of and premium, if any, and interest on the Securities of such series shall not be determined with reference to an index, formula or other similar method.

 

(15)                      Neither the Company nor the Holders of the Securities of such series shall have any right to elect the currency in which payments on the Securities of such series are made.

 

(16)                      With respect to the Securities of such series, in addition to the covenants of the Company set forth in the Indenture, the covenants set forth in the form of Security of such series attached as Annex B to the Officers’ Certificate of which this Annex A is a part under the captions “Limitation on Incurrence of Total Debt,” “Limitation on Incurrence of Secured Debt,” “Debt Service Coverage” and “Maintenance of Total Unencumbered Assets” (collectively, the “Additional Covenants”) shall be and hereby are added to the Indenture for the benefit of the Securities of such series and the Holders of the Securities of such series, and the Additional Covenants, together with the defined terms (the “Additional Definitions”) set forth in such form of Security of such series under the caption “Certain Definitions,” are hereby incorporated by reference in and made a part of this Annex A and the Indenture as if set forth in full herein and therein; provided that the Additional Definitions set forth in the Securities of such series shall only be applicable with respect to the Securities of such series and the Additional Definitions and the Additional Covenants set forth in the Securities of such series shall only be effective, insofar as they apply to the Securities of such series, for so long as any of the Securities of such series is Outstanding; provided, further, that except as set forth in (24) below, the definition of “Subsidiary” set forth in the form of certificate evidencing the Securities of such series attached as Annex B to the Officers’ Certificate of which this Annex A is a part shall only be applicable with respect to the Additional Covenants and the Additional Definitions set forth in the Securities of such series.

 

(17)                      The Securities of such series will not be issuable as Bearer Securities, and temporary global certificates will not be issued.

 

(18)                      Except as otherwise provided in the Indenture with respect to the payment of Defaulted Interest on the Securities of such series, interest payable on any Security of such series on an Interest Payment Date for the Securities of such series shall be payable only to the Person in whose name that Security (or one or more Predecessor Securities of such series) is registered at the close of business on the Regular Record Date for such interest.

 

(19)                      Sections 1402 and 1403 of the Indenture shall apply to the Securities of such series, provided that (i) the Company may effect defeasance and covenant defeasance pursuant to Section 1402 and 1403, respectively, only with respect to all (and not less than all) of the Outstanding Securities of such series and (ii) in addition to the covenants specifically referred to by section number in Section 1403 of the Indenture (insofar as such covenants apply to the Securities of such series), the Additional

 

 

Covenants applicable to the Securities of such series shall also be subject to covenant defeasance pursuant to Section 1403.

 

(20)                      The Securities of such series will be authenticated and delivered as provided in Section 303 of the Indenture.

 

(21)                      The Company shall not be required to pay Additional Amounts with respect to the Securities of such series as contemplated by Section 1010 of the Indenture.

 

(22)                      The Securities of such series shall not be convertible or exchangeable into Common Stock or Preferred Stock.

 

(23)                      The Securities of such series will be senior obligations of the Company.

 

(24)                      Insofar as Section 801 of the Indenture is applicable to the Securities of such series, the term “Subsidiary,” as such term is used in Section 801(2) of the Indenture, shall have the meaning set forth in the form of Security of such series attached as Annex B to the Officers’ Certificate of which this Annex A is a part (instead of the meaning set forth in Section 101 of the Indenture), and the term “indebtedness,” as used in Section 801(2) of the Indenture, shall be deemed to include, without limitation, “Debt” and “Secured Debt” (as such terms are defined in the form of Security of such series attached as Annex B to the Officers’ Certificate of which this Annex A is a part).

 

(25)                      The provisions of Section 1011 of the Indenture shall be applicable with respect to any term, provision or condition set forth in the Additional Covenants applicable to the Securities of such series, in addition to any term, provision and condition set forth in Sections 1004 to 1008, inclusive, of the Indenture.

 

(26)                      The Securities of such series shall have such other terms and provisions as are set forth in the form of certificate evidencing the Securities of such series attached as Annex B to the Officers’ Certificate of which this Annex A is a part, all of which terms and provisions are incorporated by reference in and made a part of this Annex A and the Indenture as if set forth in full herein and therein.

 

(27)                      As used in the Indenture with respect to the Securities of such series and in the certificates evidencing the Securities of such series, all references to “premium” on the Securities of such series shall mean any amounts (other than accrued interest) payable upon the redemption of any Securities of such series in excess of 100% of the principal amount of such Securities.

 

(28)                      Payments of principal of and premium, if any, and interest on Global Securities of such series will be made by the Company by wire transfer of immediately available funds to an account maintained by the payee located in the United States.  In the event that any Securities of such series are issued in the form of Certificated Securities of such series, payments of principal of and premium, if any, and interest on such Certificated Securities of such series shall be made in the manner set forth in the form of Security of such series which appears as Annex B to the Officers’ Certificate of which this Annex A is a part and in the Indenture.Exhibit 10.39

    

    

    Certain information has been excluded from this exhibit because (i) it is not material and (ii) would be competitively
        harmful if publicly disclosed.

    

    

    Veto Cell Production and Clinical Trial Program

    

    

    This agreement is entered into between

    The University of Texas M. D. Anderson Cancer Center

    located at  1515 Holcombe Blvd, Houston,
          TX 77030, USA

    

    

    Hereunder called  MD Anderson

    

    

    and

    

    

    Cell Source Limited

    a company duly registered under the laws of the State of Israel, Company Number 514669761 having its
        principal place of business at 5 Kineret Street, Bnei Brak  5126237

    

    

    - hereinafter called Cell Source –

    

    

    This Veto Cell Production and Clinical Trial Sponsorship Agreement ("Agreement"), is effective as
        of the 19th day of February, 2019 (the "Effective Date").

    

    

    § 1 – Subject matter

     

    

    
      
        	(1)	
                Subject to MD Anderson receiving the necessary approvals, including without limitation, the approval of the applicable institutional review board (“IRB”)
                    overseeing the Program, MD Anderston will use reasonable efforts to undertake to implement  the protocol “Anti-viral central memory CD8 veto cells in haploidentical HSCT” (attached hereto as Exhibit A), such protocol as may be further
                    revised pending approval by the applicable IRB (the “Program”).

              

      

    

    

    

    
      
        	(2)	
                As outlined in the initial budget , MDA  undertakes to perform 4  production validation runs  and a Phase I/II clincial trial using veto cells in [   ]
                    patients. Based on the assessment of  results in the first [   ] patients further continuation of the study in up to [   ] patients will be considered.

              

      

    

    

    

    
      
        	(3)	
                MD Anderson, under the supervision of its Principal Investigator Richard Champlin, M.D.,   shall perform the Program in close co-operation with Cell Source
                    and shall keep Cell Source informed of the Program’s progress and all major developments concerning the Program.

              

      

    

    

    

    
      
        	(4)	
                Upon completion of each quarter  MDA  shall submit a written report to Cell Source describing the results of the Program.

              

      

    

    

    

    
      
        	(5)	
                Cell Source represents and warrants that it exclusively licenses proprietary scientific knowledge developed at the Weizmann Institute of Science by a team
                    headed by Prof. Yair Reisner, including without limitation, the Anti-viral central memory CD8 veto cells, from Yeda Research and Development Limited (“Yeda”). The Program will be conducted in cooperation with Prof. Riesner.

              

      

    

    

    

    
      
        	(6)	
                The rights to any outcomes of the treatments performed on behalf of Cell Source, to the extent that they may be protected by patent laws, will belong
                    exclusively to Yeda and fall under the existing exclusive license that Cell Source has from the Weizmann Institute through its agreement with Yeda, provided, however, MD Anderson shall have the right to use such outcomes for MD
                    Anderson’s internal academic, research and patient care purposes.

              

      

    

    

    

    
      
        	(7)	
                MD Anderson and Cell Source will promptly notify each other upon identifying any aspect of the protocol for the Program or the Program results that may
                    adversely affect the safety, well-being, or medical care of Program subjects, or that may affect the willingness of subjects to continue participation of the Program, influence the conduct of the Program, or may alter the IRB’s approval
                    to continue the Program; when possible, such findings shall be submitted to MD Anderson electronically.  MD Anderson shall promptly notify the IRB of any such events.  When Program subject safety or medical care could be directly
                    affected by Program results, then notwithstanding any other provision of this Agreement, MD Anderson will send Program subjects a written communication about the results.

              

      

    

     

    
      
        

    

    
     § 2 – Payment

     

    

    In support of  MD Anderson’s participation in the Program hereunder, Cell Source shall pay to  MD Anderston  the sums as
        described in the attached budget (attached hereto as Exhibit B).

    

    

    § 3 – Confidentiality

     

    
      	
              (1)

            	
              Any Confidential Information that will be exchanged between the Parties, whether orally, in writing or by any
                  other medium, during the course of the Program under this agreement, shall be treated confidential by the receiving Party. The receiving Party shall not use such Confidential Information for any purpose other than performance of this
                  agreement, and shall not make available such Confidential Information to any third party.

            

    

    

    

    
      	
              (2)

            	
              For the purposes of this agreement, “Confidential Information” shall mean any information that is expressly
                  marked as confidential by appropriate means, or clearly identifiable as being confidential by its nature. However, “Confidential Information” shall not include any information that

            

    

    

    

    
      	
              -

            	
              was known to the receiving Party prior to its disclosure, or

            

    

    
      	
              -

            	
              was known to the public or was generally available prior to its disclosure, or

            

    

    
      	
              -

            	
              became known to the public or became generally available after disclosure through no wrongful act or omission of
                  the receiving Party, or

            

    

    
      	
              -

            	
              essentially corresponds to information that was disclosed or made available to the receiving Party at any time by
                  a third party, who, to the knowledge of the receiving Party, had the legal right to disclose the information to the receiving Party (it is agreed that Prof. Reisner, his team or anyone from the Weizmann Institute deriving its information
                  from the technology developed by Prof. Reisner while at the Weizmann Institute are not considered third party to this matter),

            

    

    
      	
              -

            	
              was developed independently by the receiving Party without knowledge of the Confidential Information,

            

    

    
      	
              -

            	
              is required to be disclosed in order to obtain the informed consent from subjects who may wish to enroll in the
                  Program, provided, however, that the Confidential Information will be disclosed only to the extent necessary and will not be provided in answer to unsolicited inquiries by telephone or to individuals who are not eligible Program
                  candidates,

            

    

    
      	
              -

            	
              is disclosed to a Program subject for the safety or well-being of the Program subject.

            

    

    

    

    
      	
              (3)

            	
              Notwithstanding the foregoing, each receiving Party will be permitted to disclose Confidential Information as
                  required by law or regulation, provided to the extent practicable, prior to such disclosure, the receiving Party will provide reasonable advance notice to the disclosing Party to allow the disclosing Party an opportunity to obtain a
                  protective order.

            

    

    

    

    
      	
              (4)

            	
              Each Party shall ensure that its respective employees will be bound by these confidentiality obligations.

            

    

    

    

    § 4 – Publications

    

    
      	
              (1)

            	
              Notwithstanding anything to the contrary herein, Cell Source ackowledges that MDA has the first right to
                  publishe the results of Program. Any publication in whatever form on the data and results of the Program by MD Anderson, shall be submitted to Cell Source in advance. Cell Source will review the manuscript and provide comments within 30
                  days. If Cell Source does not react within such 30 days, Cell Source shall be deemed to not have any comments on the publication. Cell Source will also have the right to publish press releases regarding the Program, provided, however, all
                  press releases including the name of MD Anderson requires prior written approval from MD Anderson’s Department of External Communications. All such publication and press releases shall be in accordance with generally acceptable scientific
                  research and/or academic standards.

            

    

    

    

    
      	
              (2)

            	
              Cell Source may request a delay of the publication for a period not to exceed sixty (60) days, or changes to
                  its content, only insofar as necessary to avoid undue disclosure of Cell Source’s Confidential Information, provided, in no case shall MD Anderson be required to remove any data or results of the Program. Should Cell Source or Yeda elect
                  to file a patent regarding a new invention that results from this Program, Cell Source may request a delay of the publication for a period not to exceed sixty (60) days if the publication discloses the content of such patent application.

            

    

    

    

    
      2

      
        

    

    § 5 – Liability

    

    

    
      	
              (1)

            	
              MDA shall perform the Program hereunder with its usual care and on the basis of the current state of the art
                  in science and technology research and in accordance with  all relevant laws and regulations required in the MDA’s domicile. With respect to the Results, no warranty of any kind is given, neither express nor implied, as to the Results’
                  fitness for any particular purpose or to the non-infringement of any third party’s rights by the Results.

            

    

    

    

    
      	
              (2)

            	
              Any liability among the contracting parties shall be limited to gross negligence and willful misconduct.
                  Except in cases of willful misconduct, neither party shall be liable for any remote or incidental damage or loss (such as loss of profit or loss of contract).

            

    

    

    

    
      	
              (3)

            	
              This Agreement does not obligate any of the contracting parties to provide medical treatment, except to the
                  extent required by applicable law, nor does this Agreement obligate either party to provide reimbursement for medical treatment if a Program subject requires medical treatment for physical illness or injury sustained as a direct result of
                  the treatment of such Program subject in accordance with this Agreement and the protocol for the Program.

            

    

    

    

    § 6 – Term

      

    

    
      	
              (1)

            	
              This agreement shall enter into force upon signature by both parties.

            

    

    

    

    
      	
              (2)

            	
              This agreement may not be terminated prematurely by either Party, except in case of “good cause for
                  termination” as per the pertinent regulations in MDA’s domicile.

            

    

    

    

    § 7 – Miscellaneous

    

    
      	
              (1)

            	
              This agreement may only be amended by written agreement of the Parties.

            

    

    

    

    Signatures

    

    

    THE UNIVERSITY OF TEXAS

    M.D. ANDERSON CANCER CENTER

    Houston, Texas

    

    

    

    

    Name

    Title

    

    

    Read and Understood:

    

    

    

    

    __________________________

    Principal Investigator

    Richard Champlin

    

    

    CELL SOURCE LIMITED

    Israel

    

    

    

    

    __________________________

    Itamar Shimrat

    Chief Executive Officer

    

    

     

    Brackets ( [   ] ) indicate that certain information has been excluded from this exhibit because (i) it
        is not material and (ii) would be competitively harmful if publicly disclosed.

    

    

    
      3

      
        

    

    Exhibit A

    Protocol

    

    

    [   ]

    

    

    

    

    

    

    

    

    

    

    

    

    

    

    Brackets ( [   ] ) indicate that certain information has been excluded from this exhibit because (i) it
        is not material and (ii) would be competitively harmful if publicly disclosed.

    

    

    
      4

      
        

    

    

    

    

    
      	
              EXHIBIT B- BUDGET

               

              Funding Agency:

            	
               

               

              Cell Source Limited

            	 	 
	
              Principal Investigator:

            	
              Champlin, Richard

            	 
	
              Title:

            	
              Role of Veto Cells in Haploidentical Transplantation for Myeloma

            	 
	
              Project Dates:

            	
              TBD

            	 	 	 
	
              Protocol(s)

            	
              2018-0221

            	 	 	 
	
              Total Patients

            	       [    ]

            	 	 	 
	
               

              [    ]

            	 	 	 	 

    

    

    

     

    

    

    	 	 	 	Year 1	 	 	 	Year 2

            	 	 	 	Grand Total	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	
            Total Costs

          	 	
            $

          	
            1,162,760.38

          	 	 	
            $

          	
            889,624.93

          	 	 	
            $

          	
            2,052,385.31

          	 

    

    

    

    

    PAYMENT SCHEDULE

    Payment Plan

    Milestone/Deliverable

    	[    ]

          	 	 	Payment
              (USD)	 
	[    ]	

          	 	
            $   473,288.26

          	 
	[    ]	

          	 	
            $   258,144.93

          	 
	[    ]	

          	 	
            $   384,456.83

          	 
	[    ]	

          	 	
            $   468,247.65

          	 
	[    ]	

          	 	
            $   468,247.65

          	 
	
                    Total

          	 	
            $2,052,385.31

          	 

    

    

    

    

    

    

    Brackets ( [   ] ) indicate that information has been excluded from this exhibit because (i) it is not material and (ii) would be competitively harmful if publicly disclosed.
     

      

      

  5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}]]